Dimethicone (Simethicone) Veterinary Grade API is a polydimethylsiloxane–fumed silicon dioxide composite supplied as a translucent, greaseless viscous liquid or semi-solid paste. The product is standardised as an antifoam-active ingredient for veterinary tablets, hard gelatin capsules, injectable suspensions, dispersible powders, granules, feed premixes, and oral solutions. Compendial identity is defined by the USP-NF Simethicone monograph and the Ph. Eur. Simeticone monograph; no uniform model designation exists across manufacturers. Where a model code is required in a dossier or specification sheet, the identifier typically encodes the nominal kinematic viscosity of the polydimethylsiloxane base, the silicon dioxide content, and the microbial quality tier. For example, VET-SIM-1000-5 is a representative code form for a 1000 cSt base fluid with 5% silicon dioxide; the commercial code should be reconciled with the certificate of analysis and the monograph name. The polydimethylsiloxane fraction is controlled at 90.5–99.0%, and the silicon dioxide fraction at 4.0–7.0%. Relative to technical antifoam fluids, the veterinary API differs by assayed silicone content, controlled elemental impurities, residual solvent documentation under VICH GL18, and endotoxin control for parenteral presentations.

The product is not a single chemical species but a structured composite. The silicon dioxide component is deliberately included and is not an impurity. This distinction matters when the product is compared with simple dimethicone fluids, which are Newtonian or near-Newtonian and do not provide the same defoaming persistence in aqueous veterinary gastrointestinal contents.

Which Pharmacopoeial Criteria Separate a Veterinary API from Technical Antifoam Fluid?

Technical polydimethylsiloxane antifoam fluids are not suitable for veterinary active use because their silica content, volatile cyclic siloxanes, and catalyst residues are not released under a compendial monograph. The USP-NF Simethicone monograph defines the composite by polydimethylsiloxane content and silicon dioxide content rather than by viscosity alone. Identification is confirmed by infrared absorption with characteristic Si-CH₃ deformation near 1260 cm⁻¹, Si-O-Si asymmetric stretching near 1090 cm⁻¹, and Si-C rocking near 800 cm⁻¹. The silicon dioxide component is recovered by ashing and functions as a hydrogen-bonded network that imparts interfacially active defoaming behaviour in aqueous gastrointestinal contents.

Elemental impurities are controlled under USP <232>/<233> or Ph. Eur. 5.20. Residual solvents are assessed by headspace gas chromatography under USP <467> or VICH GL18. Microbial quality for non-sterile oral dosage forms follows USP <1111> or Ph. Eur. 5.1.4; injectable grades must additionally meet bacterial endotoxin limits. The veterinary API therefore differs from an industrial antifoam not because the silicone chemistry is unique, but because the whole manufacturing stream is controlled for substances that remain in the drug product.

Dry carrier-based premixes for feed medication require adsorption of the liquid API onto silicified microcrystalline cellulose or colloidal silicon dioxide at 20–40% loading before geometric dilution in a ribbon blender. In a 1000 L paddle mixer running at 25 rpm, direct addition of the viscous silicone fluid to the dry carrier produces agglomerates on the chopper and non-uniform assay in finished feed. A sequenced addition of light mineral oil or propylene glycol at 0.5–1.5% of the batch mass reduces segregation of the silicone-coated carrier. For wet-granulated products, the API is emulsified in the aqueous binder phase using polysorbate 80 at 0.5–2.0% of the granulation liquid, then sprayed at 40°C onto mannitol or dibasic calcium phosphate in a top-spray fluid-bed granulator. Drying inlet air temperature is maintained below 70°C to avoid collapse of the silica network and subsequent loss of defoaming activity.

After granulation, blend uniformity is not inferred from visual appearance because the silicone phase is translucent. Powder blend samples are extracted at defined timepoints and assayed for silicon as a marker; acceptance is typically 90.0–110.0% of label claim with relative standard deviation below 5.0%. In feed premixes, the API is often diluted to 5–10% simethicone active before addition to the final feed at 0.1–0.5 kg/tonne depending on the target dose. Segregation potential is evaluated by airflow-induced fluidisation; particles below 100 µm cause dusting and non-homogeneous feed distribution, so granulation to 150–850 µm is preferred. A near-infrared method may be used for at-line blend homogeneity after calibration against the silicon assay, but calibration must account for moisture because water absorbed by fumed silica changes the NIR baseline.

If Parenteral Administration Is Intended, What Limits Apply Beyond the Oral Monograph?

Injectable-grade simethicone is a dispersed composite rather than a true solution. The silica network creates a yield stress that complicates terminal sterilisation and filterability. For parenteral formulations, the API is usually dispersed in a non-aqueous vehicle and terminally sterilised, or the finished product is aseptically processed after sterile filtration of the vehicle and separate sterilisation of the silicone phase. Sterilising-grade filtration of the complete simethicone dispersion through a 0.22 µm membrane is often not possible because silica agglomerates exceed the membrane pore rating; a 5 µm polyethersulfone prefilter followed by a 0.45 µm membrane is used for bioburden reduction before aseptic filling. Autoclaving at 121°C for 15 min can induce viscosity drift through further hydrogen bonding of the silica network, and this drift must be bounded in stability protocols.

Endotoxin testing per USP <85> or Ph. Eur. 2.6.14 is required, with acceptance limits derived from the maximum veterinary dose. Elemental impurity limits for parenteral products follow the tighter ICH Q3D parenteral exposure thresholds. The API is not a solvent for many aqueous injectable excipients; benzalkonium chloride and certain phenolic preservatives can adsorb onto the silica surface and lose antimicrobial activity, so preservative efficacy testing per USP <51> is required for multi-dose containers. If a clear injectable solution is required, a low-viscosity dimethicone of 20–100 cSt may be used without silicon dioxide, but it will not meet the Simethicone monograph definition and its antifoam activity in aqueous physiological fluids is greatly reduced. This substitution is therefore not equivalent and cannot be described as simethicone veterinary API.

In oral solutions and drench formulations, the API is suspended as a 20–30% silicone phase in an aqueous vehicle thickened with microcrystalline cellulose/carboxymethylcellulose sodium or carbomer at 0.3–0.6%. High-shear dispersion at 3000 rpm for 15–20 min is required to break silica agglomerates; vessel vacuum of −0.8 bar aids deaeration and prevents foam entrapment during mixing. pH is held between 4.5 and 7.5 to avoid hydrolysis of the silicone backbone; outside this range, the viscosity of the suspension drifts and the defoaming half-life shortens. Freezing is avoided because ice crystal formation ruptures the silica network and causes irreversible sedimentation.

Oral solutions are filled into amber Type III glass or high-density polyethylene bottles with headspace inert gas if the formulation contains unsaturated oils. In drench products, dosing accuracy depends on maintaining the yield stress above the draining threshold of the metering pump; too low a yield stress produces tailing and dose weight variation, while too high a yield stress prevents clean pump priming at 5–25°C. Rheological characterisation should include oscillatory amplitude sweep to determine the linear viscoelastic limit and creep testing to confirm the presence of a true yield stress rather than shear thinning alone.

Tablet Compression Windows for Silica-Structured Silicone APIs

Direct compression of simethicone is not feasible because the API is a liquid paste. The preferred method is adsorption onto a high-surface-area carrier at 1:1 to 1:2 ratio using silicon dioxide, magnesium aluminometasilicate, or crospovidone. The adsorbed powder is then blended with compressible filler, disintegrant, and lubricant. Lubricant selection is critical: magnesium stearate above 1.0% can coat the silica and reduce defoaming efficacy. Tablet hardness is maintained at 5–12 kp for uncoated tablets; higher compression forces can shear the silica network and cause surface filming of the tablet press punches. A 12-station rotary press running at 30–55 rpm typically requires forced feed to prevent sticking when the ambient relative humidity exceeds 60%.

If the formulation is moisture-sensitive, pre-drying of the carrier at 105°C for 2 h is used before adsorption. Hard gelatin capsule filling with a thixotropic simethicone gel is performed at 25±3°C using a dosing piston pump; temperature excursions above 30°C reduce gel yield stress and cause dose weight variability. Enteric coating is not usually required because the API acts in the gastrointestinal lumen, but coated tablets should be tested for disintegration per USP <701> because silicone films can delay water uptake.

Relative to a dimethicone-only API, the silica network in simethicone raises the low-shear viscosity, reduces migration in tablets, and increases defoaming capacity in aqueous systems. Relative to technical polydimethylsiloxane antifoam, the veterinary API is free of uncontrolled cyclic siloxane components, has documented elemental impurity and residual solvent data, and can be used as a registered active pharmaceutical ingredient. However, these advantages create measurable constraints: the silica network is shear-sensitive, cannot be sterile-filtered as a complete dispersion through 0.22 µm membranes, and may lose activity if dried above 70°C or autoclaved repeatedly.

Stability data for simethicone veterinary API are influenced by packaging and residual moisture. The silicone component is hydrophobic, but the fumed silica fraction adsorbs water at relative humidities above 60%, and this water uptake alters the hydrogen-bonded network. Bulk API is stored in tight high-density polyethylene drums with desiccant at 20–25°C. If the product is exposed to repeated freeze-thaw cycles, the silica network can form visible sediment that no longer redistributes under normal low-shear agitation; revalidation of homogeneity is then required. The API is dispensed by weight in a ventilated area, and stainless steel equipment is cleaned with 70% isopropanol followed by alkaline detergent.